

1. Company

ElexoPharm GmbH

Starterzentrum of Saarland University, Building A1

D-66123 Saarbrücken/ Germany

Phone: +49 (0) 681 9102893

Fax: +49 (0) 681 9102894

Email: info@elexopharm.de

URL: www.elexopharm.de

Contact: Axel Koch, MBA (CEO),

Prof. Dr. Rolf W. Hartmann (Founder & Scientific Advisor)



2. Core Competences

ElexoPharm GmbH, founded in 2005 as a spin-off of the Pharmaceutical and Medicinal Chemistry department of Saarland University headed by Professor R.W. Hartmann, is a MedChem CRO with expertise in hit finding, hit to lead optimisation and further lead optimisation. Due to our experience, we are able to provide fast identification of hits for novel targets using virtual and experimental screening procedures. Our medicinal chemists are able to quickly optimise hit and lead compounds regarding activity, selectivity and PK profile (ADMETox). In the synthetic labs, classical and modern organic chemistry (parallel and microwave assisted) is applied. In the analytical labs state of the art equipment is available like NMR, GC-MS and LC-MS.

In the last years, we focused in our own research projects on the design of mimics of endogenous compounds especially on steroidomimetics (e.g. ligands of steroid receptors and inhibitors of steroidogenic enzymes). In a short period, we succeeded to develop and patent, in each project, new classes of potent inhibitors fulfilling all criteria required for a drug to enter the preclinical evaluation. Moreover, for one of them we signed in may 2010 a collaboration and exclusive worldwide license agreement with Merck & Co., Inc. Whitehouse Station, New Jersey USA (also known as MSD outside of the US and Canada) through an affiliate to develop and commercialise novel candidates targeting aldosterone synthase for the potential treatment of cardiovascular diseases.

Recently ElexoPharm GmbH extended his expertise in the biochemistry field and is now able to offer to his customers the possibility to evaluate the biological activity of compounds on disease oriented assays (CYP11B1, CYP11B2, CYP17, CYP19, hepatic CYPs, 17beta HSD1, 17beta HSD2, estrogen receptors alpha and beta) as well as the establishment of new tests on other targets.

3. Cooperations offered

- Contract research on a fee-for-service basis